Latest news with #Form483
News18
2 days ago
- Business
- News18
Stocks To Watch: UltraTech, Eternal, RIL, ICICI Bank, HDFC Bank, And Others
Last Updated: Stocks to watch: Shares of firms like UltraTech, Eternal, RIL, ICICI Bank, HDFC Bank, Jio Financials, and others will be in focus on Monday's trade Stocks to Watch on Monday, July 21, 2025: Indian stock markets ended their third consecutive week in the red, as investors remained cautious amid a lackluster start to the earnings season and uncertainty over the US-India trade deal. On Monday, July 21, shares of UltraTech Cement, Eternal, Reliance Industries, ICICI Bank, HDFC Bank, Jio Financial, and others will be in focus. Eternal, IDBI Bank, UltraTech Cement, and PNB Housing Finance will be under the spotlight as these companies are scheduled to announce their June-quarter (Q1FY26) earnings today. Reliance Industries (RIL) RIL reported a strong start to FY26 with consolidated net profit soaring 76% year-on-year to Rs 26,994 crore. ICICI Bank The bank delivered a solid performance in Q1, with Net Interest Income rising 10.6% YoY to Rs 21,635 crore, while net profit grew 15.4% YoY to Rs 12,768 crore. HDFC Bank Jio Financial and Allianz Group, via its subsidiary Allianz Europe B.V., signed a binding agreement to form a 50:50 domestic reinsurance joint venture, targeting India's rapidly growing insurance sector. Yes Bank The bank posted a 59% YoY jump in standalone net profit for Q1FY26, rising to Rs 801 crore from Rs 502 crore a year earlier. JSW Steel The steelmaker's net profit surged to Rs 2,184 crore, up from Rs 845 crore in the same quarter last year. RBL Bank RBL Bank delivered a weak set of numbers, with Net Interest Income falling 13% YoY to Rs 1,480.6 crore and net profit plunging 46% to Rs 200 crore. JK Cement The cement maker reported a 75.5% YoY jump in net profit to Rs 324.3 crore, while revenue rose 19.4% to Rs 3,352.5 crore in Q1FY26. Warburg Pincus Private equity firm Warburg Pincus, through Currant Sea Investments B.V., has received approval from the Reserve Bank of India to acquire a 9.99% stake in IDFC First Bank. Punjab & Sind Bank The state-run lender posted a 48% rise in Q1 net profit to Rs 269 crore. Dr Reddy's Laboratories The USFDA issued a Form 483 with seven observations after completing a GMP and pre-approval inspection at the company's FTO 11 formulations facility in Srikakulam, Andhra Pradesh. view comments Location : New Delhi, India, India First Published: July 21, 2025, 07:48 IST News business » markets Stocks To Watch: UltraTech, Eternal, RIL, ICICI Bank, HDFC Bank, And Others Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Dr Reddy's gets 7 USFDA observations after Srikakulam plant inspection
A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines New Delhi Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL) has received a Form 483 with seven observations from the United States Food and Drug Administration (USFDA) in a recent inspection at its formulations manufacturing plant in Srikakulam, Andhra Pradesh, according to the exchange filing. The USFDA concluded the inspection of its FTO 11 facilities, the company stated in the filing. A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines. 'We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline,' it added. Dr Reddy's Laboratories reported a 22 per cent year-on-year rise in consolidated net profit for the fourth quarter of financial year 2025, reaching ₹1,593.9 crore. The company has also announced a final dividend of ₹8 per equity share for FY 2024-25. The company's first-quarter results for FY26 are scheduled to be released on July 23.
News18
3 days ago
- Business
- News18
Dr Reddys gets seven observations from USFDA for Andhra plant
New Delhi, Jul 20 (PTI) Dr Reddy's Laboratories has received a Form 483 with seven observations from the US health regulator for its Srikakulam-based plant in Andhra Pradesh, according to a regulatory filing. The US Food and Drug Administration (USFDA) conducted the GMP and a Pre-Approval Inspection (PAI) at the formulations manufacturing facility from July 10 to 18, 2025, the Hyderabad-based drug major said in the filing. 'We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," it added. As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related Acts. PTI MSS BAL BAL Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
3 days ago
- Business
- Time of India
Dr Reddy's gets seven observations from USFDA for Andhra plant
Dr Reddy's Laboratories has received a Form 483 with seven observations from the US health regulator for its Srikakulam-based plant in Andhra Pradesh , according to a regulatory filing. The US Food and Drug Administration ( USFDA ) conducted the GMP and a Pre-Approval Inspection (PAI) at the formulations manufacturing facility from July 10 to 18, 2025, the Hyderabad-based drug major said in the filing. Explore courses from Top Institutes in Select a Course Category Management healthcare Degree Leadership Project Management Others Data Science Design Thinking CXO Cybersecurity Data Science MCA PGDM MBA Operations Management Data Analytics Digital Marketing Product Management others Public Policy Technology Healthcare Finance Artificial Intelligence Skills you'll gain: Duration: 11 Months IIM Kozhikode CERT-IIMK General Management Programme India Starts on undefined Get Details Skills you'll gain: Duration: 9 Months IIM Calcutta CERT-IIMC APSPM India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK GMPBE India Starts on undefined Get Details "We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related Acts.
The Hindu
5 days ago
- Business
- The Hindu
Dr. Reddy's formulations facility in AP gets 7 U.S. FDA observations
The U.S. Food and Drug Administration (U.S. FDA) has issued seven observations to Dr. Reddy's Laboratories after an inspection of the generic drugmaker's formulations manufacturing facility in Srikakulam, Andhra Pradesh. 'The U.S. FDA today completed a GMP and a pre-approval inspection (PAI) at our formulations manufacturing facility FTO 11 in Srikakulam, AP. The inspection was conducted from July 10-18. We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline,' Dr. Reddy's said in a filing on Friday.
